Diprivan

DRUG5 trials

Sponsors

St. Antonius Hospital, Fresenius Kabi, University of Utah, Xiangya Hospital of Central South University

Conditions

Elective SurgeryFemur Head NecrosisGeneral AnesthesiaMajor Depressive DisorderMorbid ObesityTreatment Resistant Depression

Early Phase 1

Anesthesia Depth's Influence on Postoperative Delirium

Xiangya Hospital of Central South UniversityFemur Head Necrosis

Start: 2016-11-30End: 2018-12-31Target: 80Updated: 2017-12-15

Phase 1

Burst Suppression Anesthesia for Treatment of Severe Depression

CompletedNCT02935647

University of UtahMajor Depressive Disorder

Start: 2016-10-01End: 2018-09-30Updated: 2021-06-02

Phase 2

Neural and Antidepressant Effects of Propofol (Phase 2)

WithdrawnNCT03923361

University of UtahTreatment Resistant Depression

Start: 2019-04-16End: 2024-07-31Updated: 2019-12-18

Phase 3

Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery

CompletedNCT01856998

Fresenius KabiElective Surgery, General Anesthesia

Start: 2013-05-31Updated: 2014-02-21

Phase 4

Population PK/PD of Propofol in the Morbidly Obese Patient

CompletedNCT00395681

St. Antonius HospitalMorbid Obesity

Start: 2007-09-30End: 2008-09-30Updated: 2010-10-22

Related Papers

Propofol for Treatment-Resistant Depression: A Pilot Study

The International Journal of Neuropsychopharmacology2018-09-2567 citations

Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

2011-11-0144 citations